HCA vs TSHA · P/E 17, rev $75.60B vs $640.7M cap
HCA Holdings Inc (HCA) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
HCA Holdings Inc (HCA) is a medical care facilities company listed on US.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported HCA revenue for 2025-12-31 was $75.60B. Net income was $6.78B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
Latest reported TSHA revenue for 2026-06-30 was $0. Net income was -$89.0M. TSHA currently screens at market cap $640.7M.
HCA currently screens at market cap $91.01B and trailing P/E 16.8. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the HCA and TSHA stock pages for the full models.
Not investment advice.